INT197196

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2006
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 2
Total Number 24
Disease Relevance 30.60
Pain Relevance 2.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

DURS1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 345 99.36 Very High Very High Very High
antagonist 47 92.68 High High
addiction 22 71.92 Quite High
withdrawal 25 5.00 Very Low Very Low Very Low
methadone 7 5.00 Very Low Very Low Very Low
drug abuse 6 5.00 Very Low Very Low Very Low
Buprenorphine 5 5.00 Very Low Very Low Very Low
opiate 2 5.00 Very Low Very Low Very Low
agonist 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Ulcers 2829 100.00 Very High Very High Very High
Infection 27 99.48 Very High Very High Very High
Pain 322 99.36 Very High Very High Very High
Systemic Sclerosis 644 99.28 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 14 99.28 Very High Very High Very High
Amputation 69 97.66 Very High Very High Very High
Disease 94 97.52 Very High Very High Very High
Pulmonary Hypertension 115 97.48 Very High Very High Very High
Increased Venous Pressure Under Development 46 91.60 High High
Sclerosis 46 88.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This is the second randomised placebo-controlled trial to show a reduction in the number of new DUs in susceptible patients with SSc treated with bosentan.
Negative_regulation (reduction) of DUs associated with ulcers and systemic sclerosis
1) Confidence 0.43 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.29 Pain Relevance 0.10
The primary objectives were to evaluate the effect of bosentan on the reduction of new DUs and healing of DUs in patients with SSc.
Negative_regulation (reduction) of DUs associated with ulcers and systemic sclerosis
2) Confidence 0.43 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.56 Pain Relevance 0.12
However, in those patients presenting with multiple DUs (at least four), the effect of bosentan treatment on the reduction of new DUs offers greater potential benefit.
Negative_regulation (reduction) of DUs associated with ulcers
3) Confidence 0.43 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 0.83 Pain Relevance 0
The reduction of new DUs with bosentan also did not translate into measurable decreases in pain or disability compared with placebo.
Negative_regulation (reduction) of DUs associated with pain and ulcers
4) Confidence 0.43 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.28 Pain Relevance 0.17
Recently there has been a change in the pattern of HIV infection in Italy, with a gradual decrease of the epidemic among DUs, and an increase among women who are not substance abusers [30].
Negative_regulation (decrease) of DUs associated with acquired immune deficiency syndrome or hiv infection and infection
5) Confidence 0.39 Published 2006 Journal BMC Public Health Section Body Doc Link PMC1570141 Disease Relevance 0.83 Pain Relevance 0.07
Over 24 weeks, bosentan treatment was associated with a 30% reduction in the number of new DUs compared with placebo (mean±standard error: 1.9±0.2 vs 2.7±0.3 new ulcers; p=0.04).
Negative_regulation (reduction) of DUs associated with ulcers
6) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Abstract Doc Link PMC3002766 Disease Relevance 1.91 Pain Relevance 0.21
The reduction of new DUs without effect on healing in bosentan-treated patients did not translate into a smaller ulcer burden, as was seen in the previous study.16 In this study, similar reductions in the overall number of DUs (present at baseline and/or new) occurred in both groups.
Negative_regulation (reductions) of DUs associated with ulcers
7) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.36 Pain Relevance 0.08
Based on post hoc analyses, the reduction of new DUs appeared to be greater in patients with at least four DUs at baseline.
Negative_regulation (reduction) of DUs associated with ulcers
8) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.01 Pain Relevance 0.08
A previous double-blind, randomised, placebo-controlled trial investigated the role of bosentan in the reduction of new DUs in 122 patients with SSc and a history of DUs within the previous year.16 After 16 weeks of treatment, patients receiving bosentan had a 48% reduction in the mean number of new DUs compared with placebo (1.4 vs 2.7 new ulcers; p=0.01), but there were no differences between treatments in end points assessing DU healing in the 63% of patients with active DUs at baseline.
Negative_regulation (reduction) of DUs associated with ulcers and systemic sclerosis
9) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.78 Pain Relevance 0.04
The two primary end points were the number of new DUs and the time to healing of the cardinal ulcer.
Negative_regulation (number) of DUs associated with ulcers
10) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Abstract Doc Link PMC3002766 Disease Relevance 1.78 Pain Relevance 0.19
The two primary end points were (1) the mean number of new DUs per patient assessed by the investigator up to week 24 and (2) the time to healing of the cardinal ulcer up to week 24 in patients with cardinal ulcer healing maintained for 12 or more weeks.
Negative_regulation (number) of DUs associated with ulcers
11) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 0.60 Pain Relevance 0.08
The reduction of new DUs was more pronounced among patients with multiple DUs; large numbers of new DUs were less likely to occur, and the appearance of each successive new DU was delayed in patients on bosentan compared with those on placebo.
Negative_regulation (reduction) of DUs associated with ulcers
12) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 0.88 Pain Relevance 0.06
Explanations could include (1) the expected result, given no differences in total number of DUs between treatment groups, (2) a lack of sensitivity to change and discriminative value in the current instruments used to assess hand function in SSc and (3) bosentan treatment does not improve pain and disability in spite of the reduction of new DUs.
Negative_regulation (reduction) of DUs associated with pain, ulcers and systemic sclerosis
13) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.12 Pain Relevance 0.18
The reduction of new DUs without effect on healing in bosentan-treated patients did not translate into a smaller ulcer burden, as was seen in the previous study.16 In this study, similar reductions in the overall number of DUs (present at baseline and/or new) occurred in both groups.
Negative_regulation (reduction) of DUs associated with ulcers
14) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.39 Pain Relevance 0.09
A previous double-blind, randomised, placebo-controlled trial investigated the role of bosentan in the reduction of new DUs in 122 patients with SSc and a history of DUs within the previous year.16 After 16 weeks of treatment, patients receiving bosentan had a 48% reduction in the mean number of new DUs compared with placebo (1.4 vs 2.7 new ulcers; p=0.01), but there were no differences between treatments in end points assessing DU healing in the 63% of patients with active DUs at baseline.
Spec (investigated) Negative_regulation (reduction) of DUs associated with ulcers and systemic sclerosis
15) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.68 Pain Relevance 0.05
In this randomised, placebo-controlled trial, bosentan treatment was associated with a 30% reduction in the number of new DUs over the 24-week treatment period but did not result in a treatment effect on healing of the cardinal ulcer.
Negative_regulation (reduction) of DUs associated with ulcers
16) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 0.82 Pain Relevance 0
Secondary and exploratory end points included: (1) reduction of new DUs and overall DU number (proportions of patients with no new DUs and with each number of new DUs up to week 24, time to onset of each number of new DUs up to week 24 and change from baseline to week 24 in total number of all DUs), (2) healing (time to healing of all baseline DUs and of all new DUs through week 24, and proportions of patients with healing of all DUs by the end of week 24) and (3) pain and disability parameters (changes from baseline to week 24: in pain of the cardinal ulcer and overall hand pain assessed on visual analogue scales; hand disability index (an averaged score from the three Health Assessment Questionnaire (HAQ) domains of dressing/grooming, grip and hygiene); and HAQ disability index18 19).
Negative_regulation (reduction) of DUs associated with pain and ulcers
17) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.70 Pain Relevance 0.32
The reduction of new DUs was more pronounced among patients with multiple DUs; large numbers of new DUs were less likely to occur, and the appearance of each successive new DU was delayed in patients on bosentan compared with those on placebo.
Negative_regulation (numbers) of DUs associated with ulcers
18) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 0.95 Pain Relevance 0.06
Raynaud's phenomenon is thought to be more severe and new DUs more frequent during the autumn and winter, but the numbers of new DUs in autumn/winter and spring/summer randomisation subgroups were nearly identical.
Negative_regulation (numbers) of DUs associated with ulcers
19) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.30 Pain Relevance 0.13
To verify that the effect of treatment would not vary substantially across relevant baseline subgroups, the number of new DUs up to week 24 was additionally analysed in subgroups based on predefined baseline factors associated with disease severity.
Negative_regulation (number) of DUs associated with ulcers and disease
20) Confidence 0.32 Published 2011 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002766 Disease Relevance 1.35 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox